Voyager Therapeutics (VYGR) awards director 30,000 stock options
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Voyager Therapeutics, Inc. reported that director Steven Hyman received a grant of stock options to buy 30,000 shares of common stock at an exercise price of $3.43 per share. The award was made under the company’s 2025 Stock Incentive Plan as part of its director compensation policy.
All 30,000 underlying shares vest upon the earlier of one year from the grant date or the next annual meeting of stockholders, provided he continues to serve as a director. The filing does not show any option exercises or open-market share purchases or sales associated with this grant.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Hyman Steven
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 30,000 | $0.00 | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 0 shares (Direct, null)
Footnotes (1)
- [object Object]
Key Figures
Option grant size: 30,000 shares
Exercise price: $3.43 per share
Underlying common stock: 30,000 shares
+1 more
4 metrics
Option grant size
30,000 shares
Stock Option (Right to Buy) granted to director on 2026-06-09
Exercise price
$3.43 per share
Conversion or exercise price of the granted stock option
Underlying common stock
30,000 shares
Common Stock underlying the stock option award
Option expiration
2036-06-09
Expiration date of the stock option grant
Key Terms
Stock Option (Right to Buy), 2025 Stock Incentive Plan, director compensation policy, vesting commencement date, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
2025 Stock Incentive Plan financial
"This stock option was issued pursuant to the 2025 Stock Incentive Plan of Voyager Therapeutics, Inc."
director compensation policy financial
"in accordance with its director compensation policy."
vesting commencement date financial
"The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date."
The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.
annual meeting of stockholders financial
"underlying the option vest upon the earlier of the one-year anniversary ... or the date of the next annual meeting of stockholders"
FAQ
What did Voyager Therapeutics (VYGR) disclose in this Form 4 for Steven Hyman?
Voyager Therapeutics reported that director Steven Hyman received a grant of stock options for 30,000 shares at a $3.43 exercise price. The grant was issued under the 2025 Stock Incentive Plan as part of the company’s standard director compensation program.
How many Voyager Therapeutics (VYGR) options were granted to Steven Hyman and at what price?
Steven Hyman was granted stock options covering 30,000 shares of Voyager Therapeutics common stock with a $3.43 per share exercise price. These options provide the right to buy shares in the future rather than reflecting an open-market purchase today.
When do Steven Hyman’s Voyager Therapeutics (VYGR) stock options vest?
All 30,000 Voyager Therapeutics stock options vest on the earlier of one year from the grant date or the next annual meeting of stockholders. Vesting is contingent on Hyman’s continued service as a director through that vesting date, per the footnote disclosure.
Is the Voyager Therapeutics (VYGR) Form 4 for Steven Hyman a stock sale or purchase?
The Form 4 reports a compensation-related option grant, not an open-market stock sale or purchase. It records an award of options to acquire 30,000 shares at $3.43, with no corresponding exercises or trades in Voyager Therapeutics common stock reported in this filing.
Under what plan were Steven Hyman’s Voyager Therapeutics (VYGR) options granted?
The options were issued under Voyager Therapeutics’ 2025 Stock Incentive Plan in line with its director compensation policy. This indicates the award is part of the company’s structured equity compensation program for board members rather than a discretionary market transaction.